Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270972 | 1.00 | SLC6A3 (0.34) | SLC6A3SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL3509900 | 0.93 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL4449387 | 0.82 | — | — | |
| SCHEMBL23961369 | 0.77 | SLC6A3 (0.36) | SLC6A3L3MBTL1 | |
| SCHEMBL8309067 | 0.77 | — | — | |
| SCHEMBL12384257 | 0.77 | — | — | |
| SCHEMBL22414058 | 0.77 | SLC6A3 (0.38) | SLC6A3SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL10323326 | 0.77 | — | — | |
| SCHEMBL24351608 | 0.77 | SLC6A3 (0.38) | SLC6A3SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL943444 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | GHOSH ARUN K | 2010-10-21 | — | — | US | disclosed |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | OKLAHOMA MEDICAL RESEACH FOUNDATION (US) | 2006-10-19 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267609-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE2, BACE1, PSEN2 | SLC6A3 4388/4885SMN1; SMN2 1532/4885ALDH1A1 4622/4885 |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | BACE2, BACE1, PSEN2 | SLC6A3 4271/4885SMN1; SMN2 1750/4885ALDH1A1 4645/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | SLC6A3 4188/4885SMN1; SMN2 1639/4885ALDH1A1 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.